Literature DB >> 18455472

The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons.

Craig Corcoran1, Kevin Rebe, Helen van der Plas, Landon Myer, Diana R Hardie.   

Abstract

BACKGROUND: The presence of Epstein-Barr virus (EBV) DNA in cerebrospinal fluid (CSF) is used as a marker of HIV-associated primary central nervous system lymphoma (PCNSL). In our setting, EBV DNA is frequently detected in the CSF of HIV-infected patients with miscellaneous neurological diseases and thus its presence is a poor predictor of PCNSL.
OBJECTIVES: To determine whether quantification of EBV DNA in CSF improves its diagnostic specificity for PCNSL. STUDY
DESIGN: EBV viral loads were determined on CSF samples from 55 HIV-infected patients with CNS disease.
RESULTS: Twenty of the 55 patients had detectable EBV DNA in their CSF (median viral load 6120copies/ml, range 336-1,034,000copies/ml). PCNSL was confirmed in 2 patients. Their CSF EBV loads were 1,034,000 and 15,460copies/ml, respectively. Using a cut-off of 10,000copies/ml improved the specificity and positive predictive value (PPV) compared to a qualitative result for the diagnosis of PCNSL (96% vs. 66% and 50% vs. 10%, respectively).
CONCLUSION: EBV DNA is commonly detected in CSF of HIV-infected patients. Quantitative PCR improves the diagnostic specificity, however, the PPV remains too low for it to be used as an isolated marker for PCNSL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455472     DOI: 10.1016/j.jcv.2008.03.017

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  8 in total

Review 1.  Cancer biomarkers in HIV patients.

Authors:  Richard F Ambinder; Kishor Bhatia; Otoniel Martinez-Maza; Ronald Mitsuyasu
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

2.  Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.

Authors:  Michael J Peluso; Francesca Ferretti; Julia Peterson; Evelyn Lee; Dietmar Fuchs; Antonio Boschini; Magnus Gisslén; Nancy Angoff; Richard W Price; Paola Cinque; Serena Spudich
Journal:  AIDS       Date:  2012-09-10       Impact factor: 4.177

3.  A game of viral hide and seek: miliary PML masquerading as EBV encephalitis in an HIV+ patient.

Authors:  Sarah Gheuens; Brian P Buggy; Wieslawa Tlomak; Christian Wüthrich; Igor J Koralnik
Journal:  Clin Neurol Neurosurg       Date:  2013-03-25       Impact factor: 1.876

4.  Clinical characteristics of patients with Epstein Barr virus in cerebrospinal fluid.

Authors:  Timi Martelius; Maija Lappalainen; Maarit Palomäki; Veli-Jukka Anttila
Journal:  BMC Infect Dis       Date:  2011-10-21       Impact factor: 3.090

5.  Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation.

Authors:  Tommaso Lupia; Maria Grazia Milia; Cristiana Atzori; Sara Gianella; Sabrina Audagnotto; Daniele Imperiale; Lorenzo Mighetto; Veronica Pirriatore; Gabriella Gregori; Filippo Lipani; Valeria Ghisetti; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  AIDS       Date:  2020-03-01       Impact factor: 4.632

6.  Detection of human herpesviruses in the cerebrospinal fluid from patients diagnosed with or suspected of having progressive multifocal leukoencephalopathy.

Authors:  Kazuo Nakamichi; Naoki Inoue; Toshio Shimokawa; Ichiro Kurane; Chang-Kweng Lim; Masayuki Saijo
Journal:  BMC Neurol       Date:  2013-12-13       Impact factor: 2.474

7.  A Case of Varicella-Zoster Virus Meningomyelitis in an HIV-1-Infected Patient: Facing the Challenges Related to Its Management and Prognosis.

Authors:  Catarina Lameiras; Rita Patrocínio de Jesus; Bárbara Flor-de-Lima; Joana Silva; Patrícia Pacheco
Journal:  Cureus       Date:  2022-08-03

Review 8.  Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors.

Authors:  Weiwei Yan; Tingting Xu; Hui Zhu; Jinming Yu
Journal:  Onco Targets Ther       Date:  2020-01-23       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.